PINK
CLVLY

Clinuvel Pharmaceuticals Ltd ADR

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Clinuvel Pharmaceuticals Ltd ADR Stock Price

Vitals

Today's Low:
$10.34
Today's High:
$10.8
Open Price:
$10.34
52W Low:
$9.1521
52W High:
$19.98
Prev. Close:
$10.96
Volume:
17300

Company Statistics

Market Cap.:
$634.90 million
Book Value:
2.817
Revenue TTM:
$70.89 million
Operating Margin TTM:
57.17%
Gross Profit TTM:
$56.92 million
Profit Margin:
37.24%
Return on Assets TTM:
18.36%
Return on Equity TTM:
21.42%

Company Profile

Clinuvel Pharmaceuticals Ltd ADR had its IPO on under the ticker symbol CLVLY.

The company operates in the Healthcare sector and Biotechnology industry. Clinuvel Pharmaceuticals Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of Clinuvel Pharmaceuticals Ltd ADR opened at $10.34 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $10.34 - $10.8, and closed at $10.62.

This is a -3.1% slip from the previous day's closing price.

A total volume of 17,300 shares were traded at the close of the day’s session.

In the last one week, shares of Clinuvel Pharmaceuticals Ltd ADR have slipped by -13.34%.

Clinuvel Pharmaceuticals Ltd ADR's Key Ratios

Clinuvel Pharmaceuticals Ltd ADR has a market cap of $634.90 million, indicating a price to book ratio of 8.4651 and a price to sales ratio of 10.6338.

In the last 12-months Clinuvel Pharmaceuticals Ltd ADR’s revenue was $70.89 million with a gross profit of $56.92 million and an EBITDA of $40.94 million. The EBITDA ratio measures Clinuvel Pharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Clinuvel Pharmaceuticals Ltd ADR’s operating margin was 57.17% while its return on assets stood at 18.36% with a return of equity of 21.42%.

In Q2, Clinuvel Pharmaceuticals Ltd ADR’s quarterly earnings growth was a positive 93% while revenue growth was a positive 19.2%.

Clinuvel Pharmaceuticals Ltd ADR’s PE and PEG Ratio

Forward PE
0
Trailing PE
48.7308
PEG
0

Its diluted EPS in the last 12-months stands at $0.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clinuvel Pharmaceuticals Ltd ADR’s profitability.

Clinuvel Pharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 9.6704 and a EV to EBITDA ratio of 17.015. Its price to sales ratio in the trailing 12-months stood at 10.6338.

Clinuvel Pharmaceuticals Ltd ADR stock pays annual dividends of $0.04 per share, indicating a yield of 0.22% and a payout ratio of 6.2%.

Balance sheet and cash flow metrics

Total Assets
$143.95 million
Total Liabilities
$13.73 million
Operating Cash Flow
$-188997.00
Capital Expenditure
$188997
Dividend Payout Ratio
6.2%

Clinuvel Pharmaceuticals Ltd ADR ended 2024 with $143.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $143.95 million while shareholder equity stood at $125.56 million.

Clinuvel Pharmaceuticals Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $13.73 million in other current liabilities, 151849375.00 in common stock, $-38402428.00 in retained earnings and $185030.00 in goodwill. Its cash balance stood at $121.51 million and cash and short-term investments were $121.51 million. The company’s total short-term debt was $315,068 while long-term debt stood at $0.

Clinuvel Pharmaceuticals Ltd ADR’s total current assets stands at $140.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $16.20 million compared to accounts payable of $259199.00 and inventory worth $1.83 million.

In 2024, Clinuvel Pharmaceuticals Ltd ADR's operating cash flow was $-188997.00 while its capital expenditure stood at $188997.

Comparatively, Clinuvel Pharmaceuticals Ltd ADR paid $0.06 in dividends in 2024.

Other key metrics

Current Trading Price
$10.62
52-Week High
$19.98
52-Week Low
$9.1521
Analyst Target Price
$

Clinuvel Pharmaceuticals Ltd ADR stock is currently trading at $10.62 per share. It touched a 52-week high of $19.98 and a 52-week low of $19.98. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $12.17 and 200-day moving average was $13.42 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 1.9% are held by institutions.

Frequently Asked Questions About Clinuvel Pharmaceuticals Ltd ADR

The stock symbol (also called stock or share ticker) of Clinuvel Pharmaceuticals Ltd ADR is CLVLY

The IPO of Clinuvel Pharmaceuticals Ltd ADR took place on

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$160.25
-4.9
-2.97%
Datadog Inc (DDOG)
$98.22
-3.66
-3.59%
$307.7
-6.3
-2.01%
Carlsberg A/S (CABJF)
$136.86
0.91
+0.67%
$1838.6
-45.35
-2.41%
SintokogioLtd (SILDF)
$7.48
-0.07
-0.93%
$51.79
-0.77
-1.47%
$5.1
0
0%
$266.45
-5.1
-1.88%
$0.01
0
+8%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People’s Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Address

535 Bourke Street, Melbourne, VIC, Australia, 3000